Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
PepGen Inc. - Common Stock
(NQ:
PEPG
)
3.830
-0.050 (-1.29%)
Delayed Quote
Updated: 3:53 PM EST, Nov 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about PepGen Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
PepGen Announces Pricing of $125 Million Public Offering
November 11, 2026
From
PepGen Inc.
Via
Business Wire
PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
November 10, 2026
From
PepGen Inc.
Via
Business Wire
PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
November 10, 2026
From
PepGen Inc.
Via
Business Wire
PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures
November 10, 2026
From
PepGen Inc.
Via
Business Wire
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 06, 2026
From
PepGen Inc.
Via
Business Wire
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
August 06, 2026
From
PepGen Inc.
Via
Business Wire
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
May 21, 2026
From
PepGen Inc.
Via
Business Wire
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 12, 2026
From
PepGen Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
April 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
April 21, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
April 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
April 07, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
March 31, 2026
From
Pomerantz LLP
Via
GlobeNewswire
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
March 30, 2026
From
PepGen Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
March 24, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
March 17, 2026
From
Pomerantz LLP
Via
GlobeNewswire
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
March 04, 2026
From
PepGen Inc.
Via
Business Wire
PepGen Announces Regulatory Updates on FREEDOM2
March 04, 2026
From
PepGen Inc.
Via
Business Wire
PepGen to Participate in the Leerink Global Healthcare Conference
March 03, 2026
From
PepGen Inc.
Via
Business Wire
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
December 09, 2025
From
PepGen Inc.
Via
Business Wire
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
December 08, 2025
From
PepGen Inc.
Via
Business Wire
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
November 12, 2025
From
PepGen Inc.
Via
Business Wire
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 12, 2025
From
PepGen Inc.
Via
Business Wire
PepGen to Participate in Upcoming Investor Conferences
November 03, 2025
From
PepGen Inc.
Via
Business Wire
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
October 02, 2025
From
PepGen Inc.
Via
Business Wire
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
September 26, 2025
From
PepGen Inc.
Via
Business Wire
PepGen Announces Pricing of $100 Million Public Offering
September 24, 2025
From
PepGen Inc.
Via
Business Wire
PepGen Announces Proposed Public Offering
September 24, 2025
From
PepGen Inc.
Via
Business Wire
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
September 24, 2025
From
PepGen Inc.
Via
Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
August 11, 2025
From
Faruqi & Faruqi, LLP
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.